Singh Vinit, Gor Dhairya, Gupta Varsha, Jacob Aasems, Du Doantrang, Eltoukhy Hussam, Meghal Trishala
Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA.
Department of Internal Medicine, Jersey Shore University Medical Center, Neptune, NJ 07753, USA.
World J Oncol. 2022 Aug;13(4):159-171. doi: 10.14740/wjon1504. Epub 2022 Aug 23.
Gastrointestinal tract is the most common site of extranodal non-Hodgkin lymphoma (EN-NHL). Most of the published data have been on gastric NHL with limited studies on primary intestinal non-Hodgkin lymphoma (PI-NHL) considering rare incidence. We performed epidemiological and survival analysis for PI-NHL from the Surveillance, Epidemiology, and End Results (SEER) 18 database.
A total of 9,143 PI-NHL cases of age ≥ 18 years were identified from the SEER 18 database for the period 2000 - 2015. Totally, 8,568 patients were included for survival analysis. Cause-specific survival (CSS) and overall survival (OS) analysis were done for PI-NHL and PI-diffuse large B-cell lymphoma (PI-DLBCL) using sex, age of onset, treatment, histology, stage, and year of diagnosis. Survival analysis was done by using Cox proportional hazard model and Kaplan-Meier plot with log-rank test.
The percentage of PI-NHL of all the intestinal cancers and EN-NHL were 1.35%, and 10.52%, respectively. The age-adjusted incidence was 0.9145/100,000 population for the study population. PI-NHL was more common among patients aged ≥ 60 years, male and non-Hispanics Whites. Majority of patients were diagnosed at stage 1 and 2 (74%), and DLBCL (44.8%) was the most common histology. Overall median survival was 111 (95% confidence interval (CI): 105 - 117) months. In OS analysis, significant increased risk of mortality was seen with T-cell NHLs vs. DLBCL (hazard ratio (HR): 2.56), patients aged ≥ 60 vs. < 60 years (HR: 2.87), stage 4 vs. stage 1 (HR: 1.93), male vs. female (HR: 1.17), with best outcome seen in patient treated with combination of chemotherapy and surgery vs. none (HR: 0.45). Similar results were seen in CSS and for PI-DLBCL as well. Significant improvement in outcomes was observed for PI-DLBCL patients receiving chemotherapy with/without surgery.
Findings from our large, population-based study reveal PI-NHL is a rare type of intestinal malignancy with significant difference in survival based on histological and epidemiological characteristics.
胃肠道是结外非霍奇金淋巴瘤(EN-NHL)最常见的发病部位。大多数已发表的数据集中在胃非霍奇金淋巴瘤,而关于原发性肠道非霍奇金淋巴瘤(PI-NHL)的研究有限,因为其发病率较低。我们利用监测、流行病学和最终结果(SEER)18数据库对PI-NHL进行了流行病学和生存分析。
从SEER 18数据库中识别出2000 - 2015年期间年龄≥18岁的9143例PI-NHL病例。总共纳入8568例患者进行生存分析。使用性别、发病年龄、治疗方法、组织学类型、分期和诊断年份,对PI-NHL和PI-弥漫性大B细胞淋巴瘤(PI-DLBCL)进行特异性生存(CSS)和总生存(OS)分析。生存分析采用Cox比例风险模型和带有对数秩检验的Kaplan-Meier曲线。
PI-NHL在所有肠道癌症和EN-NHL中的占比分别为1.35%和10.52%。研究人群的年龄调整发病率为0.9145/10万人口。PI-NHL在年龄≥60岁、男性和非西班牙裔白人患者中更为常见。大多数患者在1期和2期被诊断(74%),弥漫性大B细胞淋巴瘤(44.8%)是最常见的组织学类型。总体中位生存期为111个月(95%置信区间(CI):105 - 117)。在OS分析中,T细胞非霍奇金淋巴瘤与弥漫性大B细胞淋巴瘤相比,死亡风险显著增加(风险比(HR):2.56);年龄≥60岁与<60岁的患者相比(HR:2.87);4期与1期相比(HR:1.93);男性与女性相比(HR:1.17);接受化疗与手术联合治疗的患者预后最佳,与未接受治疗的患者相比(HR:0.45)。CSS分析和PI-DLBCL分析也得到了类似结果。接受化疗联合或不联合手术治疗的PI-DLBCL患者的预后有显著改善。
我们基于人群的大型研究结果显示,PI-NHL是一种罕见的肠道恶性肿瘤,其生存情况在组织学和流行病学特征方面存在显著差异。